GNB4 combined with Riplet demonstrated sensitivities of 75.76% and 93.55% for stage I and stage II HCC detection, respectively, and 88.16% for stage III – VI in the entire sample cohort, indicating that the combined diagnosis of the two genes had good sensitivities in early and late HCC detection (Figure 7k). Here, GNB4 is linked to hepatocellular carcinoma.